6.00

6.26% 0.41

Aligos Therapeutics Inc (ALGS)

Overview News Price History Option Chain Financials Why ALGS Down? Discussions Forecast

Aligos Therapeutics Inc stock is traded at $6.00, with a volume of 46,167. It is up +6.26% in the last 24 hours and up +20.98% over the past month. Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

Previous Close:

$5.59

Open:

$5.65

24h Volume:

46,167

Relative Volume:

0.23

Market Cap:

$36.88M

Revenue:

$4.71M

Net Income/Loss:

$-90.32M

P/E Ratio:

-0.6894

EPS:

-8.7032

Net Cash Flow:

$-85.19M

1W Performance:

+9.39%

1M Performance:

+20.98%

6M Performance:

-32.19%

1Y Performance:

-24.23%

1-Day Range:

$5.44

$6.03

1-Week Range:

$5.3216

$6.03

52-Week Range:

$4.80

$13.69

Aligos Therapeutics Inc Stock (ALGS) Company Profile

Name

Aligos Therapeutics Inc

Sector

Healthcare (1097)

Industry

Biotechnology (615)

Phone

(800) 466-6059

Address

ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

ALGS's Discussions on Twitter

Compare ALGS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALGS Aligos Therapeutics Inc	5.96	35.71M	4.71M	-90.32M	-85.19M	-8.7032
VRTX Vertex Pharmaceuticals Inc	528.50	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	647.30	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	926.00	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.72	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	188.90	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-19-26	Resumed	Jefferies	Buy
Aug-18-25	Resumed	H.C. Wainwright	Buy
Aug-19-24	Initiated	H.C. Wainwright	Buy
Jan-06-23	Upgrade	Jefferies	Hold → Buy
Jan-06-23	Upgrade	Piper Sandler	Neutral → Overweight
Mar-23-22	Downgrade	Piper Sandler	Overweight → Neutral
Jan-07-22	Downgrade	JP Morgan	Overweight → Neutral
Jan-06-22	Downgrade	Jefferies	Buy → Hold
Sep-09-21	Initiated	SVB Leerink	Outperform
May-17-21	Resumed	Piper Sandler	Overweight
Nov-10-20	Initiated	Cantor Fitzgerald	Overweight
Nov-10-20	Initiated	JP Morgan	Overweight
Nov-10-20	Initiated	Jefferies	Buy
Nov-10-20	Initiated	Piper Sandler	Overweight

View All

Aligos Therapeutics Inc Stock (ALGS) Latest News

Jul 01, 2026

Discipline and Rules-Based Execution in ALGS Response - Stock Traders Daily

Jul 01, 2026

Jun 29, 2026

Form 4 Aligos Therapeutics Inc For: 29 June By Investing.com - Investing.com South Africa

Jun 29, 2026

Aligos Therapeutics (ALGS) director granted 5,860 stock options at $5.50 - Stock Titan

Jun 29, 2026

Aligos Therapeutics (ALGS) director granted 5,860 stock options at $5.50 strike - Stock Titan

Jun 29, 2026

Aligos Therapeutics (ALGS) director granted 5,860 options at $5.50 strike - Stock Titan

Jun 29, 2026

Director at Aligos (ALGS) granted option on 5,860 common shares - Stock Titan

Jun 29, 2026

Aligos Therapeutics (ALGS) director gets 5,860-share stock option grant - Stock Titan

Jun 29, 2026

Aligos Therapeutics (ALGS) director receives stock options for 5,860 shares at $5.50 - Stock Titan

Jun 29, 2026

Aligos Therapeutics, Inc.(NasdaqCM:ALGS) added to Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026

Aligos Therapeutics, Inc.(NasdaqCM: ALGS) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026

Aligos Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALGS) - TradingView

Jun 29, 2026

Aligos Therapeutics, Inc.(NasdaqCM: ALGS) added to Russell Microcap Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Aligos Therapeutics, Inc.(NasdaqCM: ALGS) added to Russell 3000E Value Benchmark - marketscreener.com

Jun 28, 2026

Jun 26, 2026

Aligos Therapeutics Shareholders Approve Directors and Governance Changes - TipRanks

Jun 26, 2026

Aligos Therapeutics (ALGS) shareholders approve ESPP changes and annual say-on-pay - Stock Titan

Jun 26, 2026

Enterprise value to EBIT forward of Aligos Therapeutics, Inc. – NASDAQ:ALGS - TradingView

Jun 24, 2026

Enterprise value to EBITDA forward of Aligos Therapeutics, Inc. – NASDAQ:ALGS - TradingView

Jun 24, 2026

Price to earnings forward of Aligos Therapeutics, Inc. – NASDAQ:ALGS - TradingView

Jun 24, 2026

Lawrence M. Blatt Discloses Investment at Aligos Therapeutics with 5.6% Stake - TradingView

Jun 24, 2026

Aligos Therapeutics (NASDAQ: ALGS) CEO discloses 5.6% stake in Schedule 13D filing - Stock Titan

Jun 24, 2026

Jun 23, 2026